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Background: Non-surgical treatment has generally been recommended for stage II medication-related osteone-
crosis of the jaw (MRONJ) in preference to surgery. However, non-surgical treatment is not empirically effective. 
The aim of this study was to evaluate whether surgical or non-surgical treatment leads to better outcomes for stage 
II MRONJ.
Material and Methods: In this retrospective study, surgery was performed in a total of 28 patients while 24 patients 
underwent non-surgical treatment. The outcomes of both treatment approaches after 6 months were evaluated and 
statistically compared. In addition, risk factors for surgical and non-surgical treatments were assessed for each.
Results: Surgical treatment in 25 patients (89.3%) resulted in success, with failure in 3 patients (10.7%). Non-
surgical treatment was successful for 8 patients (33.3%) and failed in 16 patients (66.7%). There was therefore a 
significant difference between surgical and non-surgical treatment outcomes (P<0.01). Regarding risk factors, 
in non-surgical treatment primary diseases, medications, and drug holiday had a significant effect on outcomes 
(P<0.01). Risk factors for surgical treatment could not be clarified.
Conclusions: Surgical treatment is more effective than non-surgical treatment for stage II MRONJ, and drug holi-
day, primary disease, and medication constitute risk factors in non-surgical treatment.
Key words: Bisphosphonate, bisphosphonate-related osteonecrosis of the jaw, denosumab, management, medica-




Bisphosphonates (BPs) and denosumab are medications 
widely used to manage cancer-related conditions, in-
cluding hypercalcemia; skeletal-related events associat-
ed with bone metastasis in the context of solid tumours 
such as breast, prostate, and lung cancer; lytic lesions 
in the setting of multiple myeloma; and osteoporosis, 
osteopenia, and Paget disease (1-7). However, these 
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agents have also been reported to cause osteonecrosis 
of the jaw, commonly referred to as medication-related 
osteonecrosis of the jaw (MRONJ) (8).
MRONJ is an intractable progressive disease thought to 
be caused by dentoalveolar surgery, such as tooth extrac-
tion, periodontal surgery, and dental implant placement, 
as well as ill-fitting dentures (9-11), although around 
25% of MRONJ develop spontaneously (12). Frequency 
of MRONJ has been reported as 0.004% to 0.1% among 
patients administered oral BPs, 0.017% to 6.7% for in-
travenous BPs, and 0.04% to 1.9% for denosumab (8). 
Although relatively rare, MRONJ has potentially severe 
symptoms in many cases. Clinical presentation is usu-
ally gingival ulceration with necrotic bone exposure 
in the oral cavity. As the disease progresses it leads to 
spontaneous severe pain, purulent drainage, extraoral 
fistula, and pathological fracture (13), with consequent 
significant reduction in quality of life.
The management of MRONJ was advocated by a stag-
ing system published in an American Association of 
Oral and Maxillofacial Surgeons (AAOMS) position 
paper in 2014, which updated the AAOMS position pa-
pers of 2007 and 2009 (8) and divides MRONJ into four 
stages based on clinical and radiographic findings. This 
system, widely used for definitive diagnosis and man-
agement of MRONJ, recommends non-surgical treat-
ment except for stage III, because dentoalveolar surgery 
for MRONJ is considered hazardous and most MRONJ 
patients have advanced malignant disease. However, 
particularly for stage II patients, non-surgical treatment 
cannot improve the symptoms empirically. Thus, suit-
able management for patients with stage II MRONJ is 
controversial.
The aim of this study was to compare the therapeutic 
effects of surgical and non-surgical treatment, and to 
evaluate which mode of management is more effective 
for patients with stage II MRONJ.
Material and Methods
- Patients
This retrospective study investigated a total of 52 pa-
tients suffering from stage II MRONJ who were referred 
to the Department of Oral and Maxillofacial Surgery, 
Toshiba Rinkan Hospital, from April 2010 to April 
2015. The classification of clinical staging was based on 
clinical and radiographic features and according to the 
2014 AAOMS position paper for MRONJ. All patients 
initially underwent non-surgical treatment for at least 1 
month, including antibacterial mouth rinse, local irriga-
tion, administration of antibiotics and analgesics, and 
professional management of oral hygiene by a dental 
hygienist. After evaluation at 1 month post initiation of 
non-surgical treatment, 28 of the 52 patients underwent 
surgical treatment and 24 patients continued with non-
surgical treatment, because the initial treatment led to 
improvement of symptoms in 18 patients while the re-
maining six refused surgical intervention.
Clinical characteristics including age, gender (male or 
female), primary diseases (malignant or non-malig-
nant), medications (intravenous BP and/or denosumab 
or intraoral BP), localization (maxilla or mandible), 
drug holidays (0-3 months or >3 months), and systemic 
factors (use of corticosteroids, use of tobacco, diabetes, 
and anaemia) were compiled, and no significant differ-
ences were found between the surgical and non-surgical 
treatment groups with regard to each clinical character-
istic (Table 1).
- Clinical strategy
If it was possible to suspend BP and/or denosumab upon 
consultation with the treating physician, we performed 
surgical or non-surgical treatment with a drug holiday.
- Non-surgical treatment
Initial non-surgical treatment was continued as long 
as possible. Debridement to relieve soft tissue irrita-
tion and remove free necrotic bone fragments was also 
performed. When swelling and pain were exacerbated, 
we administered effective antibiotics (amoxicillin, cef-
triaxone, clindamycin, and/or cefcapene pivoxil) and 
analgesics (loxoprofen, acetaminophen, and/or trama-
dol hydrochloride) accompanied by incisional drainage. 
These patients also underwent strict follow-up at least 
every 2 weeks.
- Surgical treatment
Prior to the surgical treatment, we re-evaluated the size 
of lesions based on radiographic examinations, includ-
ing panoramic radiography, computed tomography, and 
magnetic resonance imaging (MRI). The surgical ap-
proach was planned according to the radiographic fea-
tures. Surgery consisted of necrotic bone resection until 
vascularization of bone tissue was confirmed. No cases 
required reconstructive surgery or bone grafting. All of 
the resected bones were histopathologically examined to 
exclude other diseases such as malignant tumours. Es-
sentially, the surgical wound was completely sutured. If 
complete closure of the surgical wound was impossible, 
the open wound was treated by inserting terramycin-
ointment gauze (Fig. 1). Antibiotics were administered 
for at least 5 days after surgery, and strict follow-up was 
conducted at least every 2 weeks.
- Evaluation of treatment outcome
The outcomes of both surgical and non-surgical treat-
ments were evaluated at 6 months’ follow-up. We de-
fined ‘Success’ as the complete disappearance of ex-
posed bone without clinical symptoms, and ‘Failure’ as 
bone exposure remaining or disease progress (Fig. 2).
- Evaluation of risk factors of outcomes
To explore the risk factors for treatment outcomes, we 
analysed the relationship between treatment outcomes 
and clinical characteristics. The clinical characteris-
tics of the non-surgical treatment group included age, 
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Fig. 1: Surgical treatment process. (A) Necrotic bone of right maxilla was resected. (B) Vascularization of bone tissue was 
confirmed. (C) Incomplete closure of the wound and insertion of terramycin-ointment gauze. (D) Necrotic bone of left man-
dible was resected. (E) Vascularization of bone tissue was confirmed. (F) The wound was completely closed.
Surgical group (n=28) Non-surgical group (n=24) P-value
Age 0.41†








IvBPs or/and denosumab 22 16




Drug holiday 1.00§ 
>3 months 12 10
0–3 months 16 14






Table 1. Clinical characteristics of surgical and non-surgical treatment groups. There was no significant difference 
between clinical characteristics of surgical and non-surgical groups.
†Using Student’s t-test. §Using the Chi-square test.
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gender, primary disease, medication, localization, drug 
holiday, and systemic factors. In addition, postsurgical 
wound (open or closed) was included for the surgical 
treatment group. Treatment outcomes were subdivided 
into success groups and failure groups.
- Statistical analysis
Continuous data are described as mean ± standard de-
viation (SD) and were analysed using Student’s t-test. 
Categorical data were analysed using the Chi-square 
test and Fisher’s exact test (less than n=5). P values of 
less than 0.01 were considered to be statistically signifi-
cant. All statistical analyses were performed with EZR 
(Saitama Medical Center, Jichi Medical University, 
Saitama, Japan), which is a graphical user interface for 
R (The R Foundation for Statistical Computing, Vienna, 
Austria). More precisely, it is a modified version of R 
commander designed to add statistical functions fre-
quently used in biostatistics.
Results
- Evaluation of treatment outcomes between surgical 
and non-surgical groups
In the surgical treatment group, we evaluated 25 of 28 
patients (89.3%) as ‘Success’ and 3 (10.7%) as ‘Failure’. 
The three ‘Failure’ patients had no lesional expansion 
and progress stage. In the non-surgical group, 8 of 24 
patients (33.3%) were evaluated as ‘Success’ and 16 
(66.7%) as ‘Failure’. Five ‘Failure’ patients had disease 
progress. There was a statistically significant difference 
between surgical and non-surgical treatment outcomes 
(P<0.01). An overview is provided in Table 2.
- Evaluation of risk factors of outcomes in the non-sur-
gical treatment group
The success group of non-surgical treatment comprised 
age (mean 80.35±11.35), gender (male/female 4:4), pri-
mary disease (malignant/non-malignant 1:7), medica-
tion (intravenous BP and/or denosumab/intraoral BP 
2:6), localization (maxilla/mandible 2:6), drug holidays 
(>3 months/0–3 months 8:0) and systemic factors (posi-
tive/negative 3:5). On the other hand, the failure group 
comprised age (mean 72.00±11.02), gender (male/fe-
male 5:11), primary disease (malignant/non-malignant 
14:2), medication (intravenous BP and/or denosumab/
intraoral BP 14:2), localization (maxilla/mandible 6:10), 
drug holidays (>3 months/0–3 months 2:14) and sys-
temic factors (positive/negative 5:11). Primary disease, 
Fig. 2: Evaluation of treatment outcome. (A) The necrotic bone exposure and pus were observed in left maxilla. (B) 
Disappearance of exposed bone and pus. (C) Bone exposure observed in right mandible. (D) Bone exposure remained 
after surgical treatment (indicated by arrow). (E) Infection and necrotic bone in left mandible. (F) Bone exposure and 
infection spread to right mandible.
Surgical group (n=28) Non-surgical group (n=24) P-value
Success 25 8
<0.01*
Failure 3(Nobody had disease progresses )
  16
  (5 patient had disease progresses )
Table. 2. Evaluation of treatment outcomes between surgical and non-surgical groups. There was a statistically signifi-
cant difference between surgical and non-surgical treatment outcomes.
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medication, and drug holiday showed a significant dif-
ference between the success group and failure group 
(P<0.01). An overview is provided in Table 3.
- Evaluation of risk factors of outcomes in the surgical 
treatment group
The success group of surgical treatment comprised age 
(mean 73.20±11.35), gender (male/female 13:12), pri-
mary disease (malignant/non-malignant 17:8), medica-
tion (intravenous BP and/or denosumab/intraoral BP 
19:6), localization (maxilla/mandible 11:14), drug holi-
days (>3 months/0–3 months 12:13), systemic factors 
(positive/negative 5:20) and postsurgical wound (open/
closed 12:13). The failure group comprised age (mean 
64.33±11.35), gender (male/female 1:2), primary disease 
(malignant/non-malignant 3:0), medication (intravenous 
BP and/or denosumab/intraoral BP 3:0), localization 
(maxilla/mandible 0:3), drug holiday (>3 months/0–3 
months 0:3), systemic factors (positive/negative 0:3) 
and postsurgical wound (open/closed 2:1).
There was no significant difference between treatment 
outcomes and clinical characteristics in the surgical 
group. An overview is provided in Table 4.
Discussion
This study revealed that surgical treatment for stage 
II MRONJ led to more effective improvement in com-
parison with non-surgical treatment (success of surgical 
treatment versus non-surgical treatment: 89.3% versus 
33.3%). In stage II MRONJ management, the suitabil-
ity of surgical or non-surgical treatment is unclear and 
controversial. The more common recent approach has 
been non-surgical treatment, and the surgical approach 
is rare because dentoalveolar surgery is considered to 
be related to the progression of MRONJ (11). However, 
non-surgical treatment is unable to achieve effective re-
sults empirically, with some authors reporting a success 
rate (complete healing) of non-surgical treatment of 17% 
to 23% (14–16). Meanwhile, some studies have reported 
a success rate of 85% to 100% for surgical treatment in 
recent years (17–20). We considered that surgical treat-
ment is more suitable than non-surgical treatment for 
stage II MRONJ.
Many MRONJ patients have been treated according to 
the staging guidelines in the AAOMS position paper, 
where surgical intervention was recommended to treat 
Success group(n=8) Failure group(n=16) P-value
Age 0.06† 








IvBPs or/and denosumab 2 14





>3 months 8 2
0–3 months 0 14




§Using Fisher’s exact test.
*Significant difference was observed.
Table 3. Evaluation of risk factors of outcomes in the non-surgical treatment group. Primary disease, medication and 
drug holiday showed a significant difference between the success group and the failure group.
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only stage III. Stage III comprises severe clinical fea-
tures such as pathological fracture, oroantral communi-
cation, severe pain, extraoral fistula, and necrotic bone 
extending beyond the region including ramus, sinus and 
zygoma. Thus, treatment of stage III has involved not 
only marginal bone resection and removal of necrotic 
bone but also segmental resection and immediate re-
construction with vascularized bone block grafting 
(21–23). However, performing such an expansive op-
eration is not always suitable for patients with malig-
nant disease. Given their poor systemic condition, bone 
grafting might lead to malignant disease metastasis. In 
general, although few patients with stage II MRONJ 
require reconstructive surgery, we consider that surgi-
cal treatment should be viewed positively for stage II 
MRONJ.
Dentoalveolar surgery has not been recommended for 
patients taking BPs, as many clinicians have reported 
MRONJ induced by tooth extraction. In fact, many cases 
of BRONJ were diagnosed after tooth extractions. In the 
present study there was no disease progress caused by 
surgical treatment. Sven et al. reported patients taking 
BP treatment for local infection control who underwent 
tooth extraction without a drug holiday, with a good re-
sult (24). Tooth extraction is indicated mainly for severe 
periodontitis and refractory periapical lesions. The de-
veloping MRONJ may therefore be involved with local 
infection control rather than the surgical intervention.
Before dentoalveolar surgery, a drug holiday has been 
generally recommended. However, we are particularly 
sceptical about the requirement for a drug holiday. In 
fact, our results indicated that there was no significant 
difference in this regard. There is currently no evidence 
that the length of drug holiday and interruption of anti-
resorptive therapy alter the risk of osteonecrosis of the 
jaw (8,25,26). Specifically, a drug holiday for a patient 
Success group(n=25) Failure group(n=3) P-value
Age 0.21† 








IvBPs or/and denosumab 19 3




Drug holiday 0.24§ 
>3 months 12 0
0–3 months 13 3
Systemic factor 1.00§ 
Positive 5 0
Negative 20 3




§Using Fisher’s exact test.
Table. 4. Evaluation of risk factors of outcomes in the surgical treatment group. There was no significant difference in 
clinical characteristics between the success group and the failure group.
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with malignant disease may result in various adverse 
events; therefore, more clear evidence is necessary re-
garding this issue.
Although some authors have reported performing sur-
gical treatment for MRONJ, the key to surgical success 
is yet to be revealed. Many studies recommend postsur-
gical wound closure in order to achieve treatment suc-
cess. However, our present results show no significant 
difference in outcome whether the wound was closed 
or open. On examining the literature reporting satisfac-
tory surgical results, we found that confirming vascu-
larized bone tissue on all resected bone surfaces is an 
important criterion (20,24,27,28). In stage II MRONJ, it 
is difficult to determine the extent of the osteonecrosis 
only by radiographic examination or MRI, because se-
questrum separation is not found. In this study, we care-
fully controlled the extent of resection until confirming 
vascularized bone tissue in the resected bone surfaces, 
which led to a satisfactory treatment outcome. We con-
sider that the postsurgical wound had no influence on 
the outcome, and that confirming bleeding from the 
resection site, namely reliable elimination of necrotic 
bone, may hold the key to surgical success in the treat-
ment of stage II MRONJ.
Our study indicated primary disease, medication, and 
drug holiday as risk factors for non-surgical treatment 
outcome, with the high-risk groups being patients with 
malignant disease, intravenous BPs and/or denosumab, 
and a 0- to 3-month drug holiday. This result has to be 
considered carefully because there are confounders in-
volved; for example, a patient with malignant disease 
being administered intravenous BPs would be unable 
to take a longer-term drug holiday. We hypothesized 
that the true risk factor in non-surgical treatment is 
malignant disease. In support of this, there have been 
no reported cases of BRONJ in children or adolescents 
on intravenous BPs (29). In addition, the US Food and 
Drug Administration reported that there was no signifi-
cant difference in BRONJ incidence between intrave-
nous BPs and oral BPs in the treatment of osteoporosis. 
These reports suggest that intravenous BP is unlikely 
to be a factor that worsens or induces MRONJ, and that 
it may not constitute a risk for non-surgical treatment. 
Meanwhile, as already noted, we must remain sceptical 
of the influence a drug holiday may have on MRONJ in-
cidence, owing to the lack of evidence. In patients with 
malignant disease, bone metabolic function becomes 
abnormal and resistance to infection is lowered because 
of malnutrition and various complications. Although 
further investigation is necessary, we consider that non-
surgical treatment may be particularly ineffective in pa-
tients with malignant disease.
Although we used the AAMOS position paper because 
of its widespread adoption, we consider that this clas-
sification is not always suitable, especially in relation 
to treatment. AAMOS classified by clinical findings 
such as presence of infection, lesional expansion, and 
symptoms, all of course very important for classify-
ing MRONJ. However, we feel that AAMOS position 
paper does not adequately consider the relationship to 
treatment efficacy. In fact based on the treatment strat-
egy in AAMOS position paper, especially in stage II, 
treatment (non-surgical) frequently failed in our result. 
Bagan et al. classify by considering the treatment ef-
ficacy of stage 2 (uncontrolled or controlled by medica-
tion) (30). We agree with this method of classification, 
because this classification include treatment strategy. 
The classification should contribute to decision mak-
ing as regards treatment methods. If the ‘Guidelines for 
MRONJ’ are to be further constituted, the classification 
has to consider treatment efficacy.
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